New Alzheimer's vaccine trial aims to slow brain damage
NCT ID NCT07167966
Summary
This study is testing a vaccine called AADvac1, designed to target a harmful protein called tau in the brain. It aims to see if the vaccine, given alone or with another Alzheimer's drug, can reduce tau buildup and slow disease progression in adults aged 50-80 with very early signs of Alzheimer's. The trial will involve 375 participants across multiple centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.